Bessemer Group Inc. Boosts Stake in Amedisys Inc (AMED)

Bessemer Group Inc. grew its holdings in Amedisys Inc (NASDAQ:AMED) by 20.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,900 shares of the health services provider’s stock after acquiring an additional 1,700 shares during the quarter. Bessemer Group Inc.’s holdings in Amedisys were worth $1,159,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Commonwealth Equity Services LLC lifted its position in Amedisys by 2.6% in the fourth quarter. Commonwealth Equity Services LLC now owns 3,704 shares of the health services provider’s stock worth $433,000 after purchasing an additional 95 shares during the period. Jennison Associates LLC lifted its position in Amedisys by 2.0% in the fourth quarter. Jennison Associates LLC now owns 6,408 shares of the health services provider’s stock worth $750,000 after purchasing an additional 126 shares during the period. First Hawaiian Bank lifted its position in Amedisys by 45.6% in the fourth quarter. First Hawaiian Bank now owns 415 shares of the health services provider’s stock worth $49,000 after purchasing an additional 130 shares during the period. ETRADE Capital Management LLC lifted its position in Amedisys by 2.2% in the fourth quarter. ETRADE Capital Management LLC now owns 6,819 shares of the health services provider’s stock worth $799,000 after purchasing an additional 148 shares during the period. Finally, State of Alaska Department of Revenue lifted its position in Amedisys by 1.8% in the fourth quarter. State of Alaska Department of Revenue now owns 9,723 shares of the health services provider’s stock worth $1,138,000 after purchasing an additional 175 shares during the period. 90.37% of the stock is owned by institutional investors.

In other Amedisys news, Director Jeffrey A. Rideout sold 1,411 shares of Amedisys stock in a transaction on Monday, March 4th. The stock was sold at an average price of $121.58, for a total transaction of $171,549.38. Following the completion of the transaction, the director now directly owns 4,557 shares of the company’s stock, valued at $554,040.06. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Christopher Gerard sold 2,500 shares of Amedisys stock in a transaction on Monday, March 11th. The shares were sold at an average price of $118.96, for a total value of $297,400.00. Following the transaction, the chief operating officer now directly owns 25,731 shares of the company’s stock, valued at $3,060,959.76. The disclosure for this sale can be found here. Over the last three months, insiders have sold 8,691 shares of company stock valued at $1,037,103. Company insiders own 2.60% of the company’s stock.

AMED has been the subject of several research reports. Zacks Investment Research raised Amedisys from a “hold” rating to a “buy” rating and set a $151.00 target price for the company in a research report on Thursday, February 7th. ValuEngine cut Amedisys from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, December 11th. BidaskClub cut Amedisys from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, December 18th. SunTrust Banks raised their target price on Amedisys to $145.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Finally, Barclays initiated coverage on Amedisys in a research report on Friday, December 14th. They issued an “equal weight” rating and a $130.00 target price for the company. Eight research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $125.55.

Shares of NASDAQ AMED opened at $124.62 on Friday. The firm has a market cap of $3.91 billion, a price-to-earnings ratio of 34.33, a P/E/G ratio of 1.52 and a beta of 1.37. Amedisys Inc has a 52-week low of $59.08 and a 52-week high of $140.91. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.01 and a quick ratio of 1.01.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings data on Wednesday, February 27th. The health services provider reported $0.91 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.85 by $0.06. The company had revenue of $434.38 million during the quarter, compared to analysts’ expectations of $427.75 million. Amedisys had a return on equity of 25.89% and a net margin of 7.18%. The business’s revenue was up 9.2% on a year-over-year basis. During the same period last year, the business earned $0.56 earnings per share. As a group, sell-side analysts predict that Amedisys Inc will post 4.04 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Bessemer Group Inc. Boosts Stake in Amedisys Inc (AMED)” was originally reported by WKRB News and is the sole property of of WKRB News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.wkrb13.com/2019/03/15/bessemer-group-inc-boosts-stake-in-amedisys-inc-amed.html.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.

Featured Story: How is inflation measured?

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.